Screener / SEC EDGAR /CIK 0001109354 /10-K filed Feb 27, 2026, compared with Mar 3, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Technology · Lab Instruments

Bruker Corp BRKR

Compare with peers Embed
What it said it expected, against what it reported

2 targets with a reported result

Releases of the last 3 years
Above the range 0 above the last range given
Within the range 1 of 2 range targets
Below the range 1 below the last range given

The numbers BRKR said it expected, in its earnings releases, next to what it then reported for the same period.

Target by target

Each target, with the sentence it came from · release and 10-Q or 10-K

The last range givenReported, abovewithin or keptbelow or missed
TargetWhat the company saidReportedResult
Diluted EPS (company-defined)
Fiscal 2026
Given $2.10 to $2.15 release Feb 12, 2026
Kept $2.10 to $2.15 release May 6, 2026
Kept $2.10 to $2.15 release Aug 4, 2026
Kept $2.10 to $2.15 release Nov 4, 2026
– No standard number
The company's words
Bruker expects FY26 non-GAAP EPS of $2.10 to $2.15, compared to $1.83 in FY25, an increase of 15% to 17% year-over-year. release Feb 12, 2026
Bruker continues to expect FY26 non-GAAP EPS of $2.10 to $2.15, compared to $1.83 in FY25, an increase of 15% to 17% year-over-year. release May 6, 2026
Bruker continues to expect FY26 non-GAAP EPS of $2.10 to $2.15 compared to $1.83 in FY25, an increase of 15% to 17% year-over-year, now at an effective non-GAAP tax rate of 27.5%. release Aug 4, 2026
Bruker continues to expect FY26 non-GAAP EPS of $2.10 to $2.15 compared to $1.83 in FY25, an increase of 15% to 17% year-over-year. release Nov 4, 2026
Diluted EPS (company-defined)
Fiscal 2025 (ended Dec 31, 2025)
Given $2.67 to $2.72 release Feb 13, 2025
Lowered $2.40 to $2.48 release May 7, 2025
Lowered $1.95 to $2.05 release Aug 4, 2025
Lowered $1.85 to $1.90 release Nov 3, 2025
– No standard number
The company's words
Bruker initiates FY 2025 guidance (with percentages year-over-year): … Non-GAAP EPS of $2.67 to $2.72; up 11% to 13%, with CER increase of 14% to 16% release Feb 13, 2025
Updated FY 2025 guidance: … Non-GAAP EPS $2.40 to $2.48, growth of 0% to 3% yoy release May 7, 2025
Bruker now expects FY 2025 non-GAAP EPS of $1.95 to $2.05, compared to FY 2024 non-GAAP EPS of $2.41. release Aug 4, 2025
Bruker now expects FY 2025 non-GAAP EPS of $1.85 to $1.90, compared to FY 2024 non-GAAP EPS of $2.41. release Nov 3, 2025
Revenue
Fiscal 2025 (ended Dec 31, 2025)
Given $3.47B to $3.54B release Feb 13, 2025
Raised $3.48B to $3.55B release May 7, 2025
$3.44B
10-K filed 2026-02-27
Below the range
The company's words
Bruker initiates FY 2025 guidance (with percentages year-over-year): … Revenue $3.47 to $3.54 billion; up 3% to 5%, with CER growth of 5% to 7% release Feb 13, 2025
Updated FY 2025 guidance: … Revenue $3.48 to $3.55 billion, up 3.5% to 5.5%, incl. organic growth of 0% to 2% release May 7, 2025
Diluted EPS (company-defined)
Fiscal 2024 (ended Dec 31, 2024)
Given $2.71 to $2.76 release Feb 13, 2024
Raised $2.79 to $2.84 release May 2, 2024
Lowered $2.59 to $2.64 release Aug 6, 2024
Lowered $2.36 to $2.41 release Nov 5, 2024
– No standard number
The company's words
Bruker expects FY 2024 non-GAAP EPS of $2.71 to $2.76, or 5% to 7% growth yoy. release Feb 13, 2024
Updated FY 2024 guidance: … Non-GAAP EPS of $2.79 to $2.84, up $0.08 from prior guidance, including ELITech EPS accretion, but excluding still pending EPS-dilutive NanoString acquisition release May 2, 2024
Bruker now expects FY 2024 non-GAAP EPS of $2.59 to $2.64, compared to FY 2023 non-GAAP EPS of $2.58. release Aug 6, 2024
Updated FY2024 guidance: … Non-GAAP EPS of $2.36 - $2.41 release Nov 5, 2024
Revenue
Fiscal 2024 (ended Dec 31, 2024)
Given $3.29B to $3.35B release May 2, 2024
Raised $3.38B to $3.44B release Aug 6, 2024
Lowered $3.34B to $3.37B release Nov 5, 2024
$3.37B
10-K filed 2025-03-03
Within the range
The company's words
Bruker now expects FY 2024 revenues of $3.29 to $3.35 billion, up $60 million from our prior guidance of $3.23 to $3.29 billion. release May 2, 2024
Bruker increases FY 2024 revenue guidance to $3.38-$3.44 billion, now including the NanoString business; implies revenue growth of 14% to 16%, and organic revenue growth of 5% to 7% yoy release Aug 6, 2024
Updated FY2024 guidance: … Revenue $3.34 to $3.37 billion, implying Bruker organic revenue growth of 3% to 4%, and CER revenue growth of approximately 13% yoy release Nov 5, 2024

Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (14 releases since 2024-02-13), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.

Sources

The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.

Also

Earnings releases: each release in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BRKR/export.csv") into a cell.

Next:Archive
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.